NUS

Nu Skin Enterprises, Inc.

Fundamental data last updated:November 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Consumer Defensive

industry

Household & Personal Products

Exchange

NYSE

County of HQ

United States

Next Earnings Date

Pending Announcement

Business Summary

Nu Skin's business model revolves around direct selling of personal care products, leveraging a vast network of independent distributors. This model creates a strong customer lock-in through personalized service and community building. The company's competitive moat lies in its brand reputation and product innovation, which drive customer loyalty. However, reliance on distributor networks can be both a strength and a vulnerability, depending on market dynamics.

 


Analyze NUS on TradingView

VALUATION

P/E

-1.07

Market Cap ($M USD)

$231.70M

Forward P/E

5.80

PEG

0.03

PRICE TO SALES

0.17

PRICE TO BOOK

0.43

EV / EBITDA

7.78

5-Year Average P/E

Free Cash Flow Yield

4.65%

DCF Value

$26.74

Graham Number

$20.48

Price to FCF

21.49

EV to FCF

28.36

Earnings Yield

-93.55%

FCF Yield

4.65%

DIVIDEND

Yield

5.04%

Annual Payout

$0.24

Payout Ratio

-5.39%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$4.45

Next Year EPS Growth Estimate

$0.82

Next Year Revenue Growth Estimate

$1.32B

Return on Equity (ROE)

-29.42%

FREE CASH FLOW

Operating Margin

-0.62%

Debt-to-Equity

0.49

Piotroski F-Score

4

Altman Z-Score

3.71

Return on Invested Capital (ROIC)

-0.97%

Current Ratio

1.98

Quick Ratio

1.24

Net Debt to EBITDA

1.88

Interest Coverage

-0.55

Gross Profit margin

69.19%

FCF PER SHARE

$0.22

REVENUE PER SHARE

$28.30

Analyze NUS on TradingView

Gainseekers Quantitative Analysis

Summary

Nu Skin Enterprises, Inc. presents a perplexing valuation scenario. Despite a deeply negative P/E ratio, the stock’s DCF value and Graham Number suggest significant undervaluation, indicating potential market mispricing. The Forward P/E of 5.80 and a robust Altman Z-score of 3.71 highlight a company with a surprising degree of financial stability and growth potential. However, the negative earnings yield and return on equity signal underlying profitability issues. The market seems to be pricing in a turnaround, but the company’s financial health remains a mixed bag.

AI Exposure / Tech Reliance

Operating in the Consumer Defensive sector, Nu Skin is positioned to leverage AI and tech advancements to enhance its supply chain and customer engagement. As a player in Household & Personal Products, integrating AI could streamline operations and personalize marketing efforts. However, the industry is not inherently tech-driven, which may slow adaptation.

The Bull Case

For the value or GARP investor, Nu Skin offers intriguing prospects. The forward PEG ratio of 0.03 suggests significant growth at a bargain price. Despite a negative ROIC, the company's FCF yield of 4.65% and a Piotroski F-Score of 4 indicate some operational strengths. The gross profit margin of 69.19% underscores strong pricing power, hinting at potential for improved capital efficiency.

The Bear Case

Nu Skin's structural weaknesses are glaring. The negative EPS and operating margin of -0.62% reflect a company struggling with profitability. The interest coverage ratio is alarmingly negative, raising concerns about its ability to service debt. While the price-to-book ratio of 0.43 suggests undervaluation, the price-to-sales ratio of 0.17 indicates potential revenue challenges. The stock's proximity to its 52-week low further underscores market skepticism.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$11.00

Institutional Ownership %

1-Year Beta

0.90

Insider Buying % (6 Mo)

Distance to 52-Week High

145.17%

Distance to 52-Week Low

6.51%

EARNINGS SURPRISE %

0.00%

50-DAY SMA

$4.77

200-DAY SMA

$6.45

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.